Compare ACCO & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACCO | NGEN |
|---|---|---|
| Founded | 1893 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Publishing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 373.2M | 317.6M |
| IPO Year | 2005 | N/A |
| Metric | ACCO | NGEN |
|---|---|---|
| Price | $3.51 | $3.95 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 608.9K | 93.7K |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | ★ 8.26% | N/A |
| EPS Growth | ★ 141.51 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $1,524,700,000.00 | N/A |
| Revenue This Year | $5.79 | N/A |
| Revenue Next Year | $4.84 | N/A |
| P/E Ratio | $8.23 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.20 | $3.73 |
| 52 Week High | $4.82 | $5.93 |
| Indicator | ACCO | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 26.37 | 40.95 |
| Support Level | $3.34 | $3.76 |
| Resistance Level | $3.86 | $4.44 |
| Average True Range (ATR) | 0.13 | 0.26 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 4.09 | 28.57 |
ACCO Brands Corp designs, manufactures, and markets consumer and business products. It operates through two segments: ACCO Brands Americas, and ACCO Brands International. The company offers school notebooks, janitorial supplies, and whiteboards; storage and organization products, sheet protectors, and indexes, and punching products; computer accessories and others used in schools, homes, and businesses. The company markets and sells its products through various channels, including mass retailers; e-tailers; discount, and variety chains; and warehouse clubs. It generates maximum profit from ACCO Brands America segment.
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.